We are delighted to welcome Hi-D Imaging AG to our growing list of portfolio companies and are pleased to support them as a strategic clinical and regulatory development partner.

Hi-D Imaging AG, an ETH Spin-off medtech company founded in July 2019, aims to revolutionize the cardiovascular sector by making personalized aortic heart valve replacement therapy a reality. The diverse team of engineers and cardiologists of Hi-D applies high precision fluid dynamics analysis and machine learning algorithms to develop the world’s first AI-based pre-operational planning platform. The platform assesses full hemodynamics in patient-specific anatomies and is offered as “Software as a Service” (SaaS).  

Hi-D’s goal is to increase the patient’s quality of life and optimize the design of next-generation heart valves. Hi-D builds a bridge between clinical teams and heart valve manufacturers to provide the best treatment for patients with cardiovascular diseases. Hi-D is planning 3 clinical proof of concept trials in Europe and in the US.

The start-ups will share more information on their journey at the HEMEX pitching event on June 5th.

The HEMEX PORTFOLIO contains a selection of the most promising Swiss and European life science start-ups. Headquartered close to the Basel global life sciences hub, our main focus to bring innovative drugs, medical devices and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business.

Leave a Reply

Your email address will not be published. Required fields are marked *